NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 23, 2026, Novo Nordisk issued a press release "announc[ing] headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme."  The press release reported that Novo Nordisk's experimental drug CagriSema failed to achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide after 84 weeks. 

On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $7.79 per ADR, or 16.43%, to close at $39.63 per ADR on February 23, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novo-nordisk-as---nvo-302698891.html

SOURCE Pomerantz LLP